RecruitingNot ApplicableNCT07281001

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Sponsor

Blokhin's Russian Cancer Research Center

Enrollment

60 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

HER2-positive Breast Cancer Trastuzumab Deruxtecan

Summary

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This observational study is collecting real-world data on how well trastuzumab deruxtecan (T-DXd, also known as Enhertu) works in Russian women with metastatic or advanced HER2-positive breast cancer, based on existing medical records. **You may be eligible if...** - You are 18 or older - You have metastatic or locally advanced breast cancer (including those who were Stage IV from diagnosis or had a recurrence) - You have received trastuzumab deruxtecan as part of your treatment - Complete medical records are available **You may NOT be eligible if...** - Your medical records are incomplete - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.